NCT06666491 is a Phase 3 clinical trial of Tafenoquine in Malaria, Vivax, sponsored by GlaxoSmithKline.

Who is sponsoring NCT06666491?

NCT06666491 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT06666491?

Interventions in NCT06666491: Tafenoquine, Primaquine, Chloroquine.

What condition does NCT06666491 study?

NCT06666491 studies Malaria, Vivax.

Is NCT06666491 still recruiting?

NCT06666491 is currently recruiting now. Last updated 7 August 2025.

Last reviewed 2025-08-07 · How we verify

NCT06666491

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting now Phase 3 Last updated 7 August 2025

What this trial tests

Phase 3 trial testing Tafenoquine in Malaria, Vivax in 300 participants. Currently enrolling.

Timeline

13 November 2024

Primary endpoint
25 May 2026

25 May 2026

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	13 November 2024
Primary completion	25 May 2026
Estimated completion	25 May 2026
Sites	4 locations across India

Drugs / interventions tested

Tafenoquine (TAFENOQUINE) — full drug profile →
Primaquine — full drug profile →
Chloroquine (CHLOROQUINE) — full drug profile →

Conditions studied

Malaria, Vivax — all drugs for Malaria, Vivax →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 2 to 64, any sex, with Malaria, Vivax. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tafenoquine

Trials testing the same drug.

NCT06575647 — Vivax Elimination With Tafenoquine (VET) Study · Phase 4 · completed
NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
NCT06207370 — Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis · Phase 2 · recruiting
NCT06148792 — A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria · Phase 3 · recruiting
NCT04984759 — Tafenoquine and Primaquine in Colostrum and Breast Milk · Phase 4 · withdrawn

Other recruiting trials for Malaria, Vivax

Currently open trials in the same condition.

NCT05788094 — ACT vs CQ With Tafenoquine for P. Vivax Mono-infection · Phase 4 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06666491 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 7 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06666491.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing